| Hazard Information | Back Directory | [Uses]
Simmitecan hydrochloride, a 9-substituted lipophilic Camptothecin (HY-16560) derivative, is a potent topoisomerase I inhibitor. Simmitecan hydrochloride is an anticancer agent[1][2]. | [in vivo]
Simmitecan hydrochloride (3.75, 7.5 and 15 mg/kg, i.v. bolus) shows mean elimination half-life t1/2 of approximately 1.4 h in SD rats[2].
| [References]
[1] Rini B, et al. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol. 2014 Sep;25(9):1794-1799. DOI:10.1093/annonc/mdu212
[2] Hu ZY, et al. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals. Acta Pharmacol Sin. 2013 Nov;34(11):1437-48. DOI:10.1038/aps.2013.74 |
|
|